| Basics |
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
|
| IPO Date: |
April 28, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$288.18M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.20 | 3.27%
|
| Avg Daily Range (30 D): |
$0.14 | 2.85%
|
| Avg Daily Range (90 D): |
$0.12 | 2.30%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.5M |
| Avg Daily Volume (30 D): |
.76M |
| Avg Daily Volume (90 D): |
.7M |
| Trade Size |
| Avg Trade Size (Sh.): |
137 |
| Avg Trade Size (Sh.) (30 D): |
98 |
| Avg Trade Size (Sh.) (90 D): |
100 |
| Institutional Trades |
| Total Inst.Trades: |
444 |
| Avg Inst. Trade: |
$1.71M |
| Avg Inst. Trade (30 D): |
$1.05M |
| Avg Inst. Trade (90 D): |
$1.12M |
| Avg Inst. Trade Volume: |
.23M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.9M |
| Avg Closing Trade (30 D): |
$1.1M |
| Avg Closing Trade (90 D): |
$1.28M |
| Avg Closing Volume: |
254.78K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.13
|
$-.16
|
|
Diluted EPS
|
|
$-.13
|
$-.16
|
|
Revenue
|
$
|
$
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -7.69M
|
$ -9.77M
|
|
Operating Income / Loss
|
$
|
$ -8M
|
$ -10.17M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 18.1M
|
$ -9.11M
|
|
PE Ratio
|
|
|
|
|
|
|
